Optimal sample size allocation and go/no‐go decision rules for phase II/III programs where several phase III trials are performed

DOI10.1002/bimj.201700241zbMath1419.62424OpenAlexW2892340806WikidataQ91292133 ScholiaQ91292133MaRDI QIDQ4967100

Stella Preussler, Marietta Kirchner, Meinhard Kieser

Publication date: 2 July 2019

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1002/bimj.201700241

zbMATH Keywords

optimizationsample sizeprobability of successdrug development programphase II/III

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sampling theory, sample surveys (62D05)

Related Items

drugdevelopR